The ResApp Health Ltd (ASX:RAP) share price is jumping on Friday after announcing a deal with AstraZeneca…
The post ResApp (ASX:RAP) share price jumps 19% on AstraZeneca deal appeared first on The Motley Fool Australia. –
At the time of writing, the digital health company’s shares are up 19% to 6.9 cents.
What did ResApp announce?
This morning ResApp announced that it has secured a one-year, non-exclusive licensing agreement with the Japanese subsidiary of global biopharmaceutical company AstraZeneca. The agreement will see ResApp license its cough counting technology for use in a program to support asthma patients in Japan.
According to the release, under the agreement, ResApp’s cough counting technology will be integrated into AstraZeneca’s direct-to-consumer asthma management smartphone application. This will then be used to assist patients in monitoring symptoms in the home setting and support them in managing their asthma.
The release notes that AstraZeneca’s asthma monitoring application is currently under development and is expected to launch in the coming months. In the meantime, ResApp will work with AstraZeneca on its integration into the smartphone application. This includes refining it to the pharmaceutical giant’s specifications for use in the Japanese market.
Management notes that this agreement will be the first time ResApp’s cough counting technology is being used outside of a clinical trial setting. It believes this highlights its broad applicability.
Furthermore, as it is the second agreement with AstraZeneca, it feel it provides further validation from an industry-leading pharmaceutical company.
What are the financial terms?
The release explains that AstraZeneca will pay an annual licence fee to ResApp for each patient provided with AstraZeneca’s asthma management smartphone application.
However, while sales of ResApp’s cough counting technology continue to grow, management does not expect this agreement to have a material impact on the company’s operating results.
ResApp’s Managing Director and CEO, Dr Tony Keating, commented: “With its Asthma Monitoring App, AstraZeneca is seeking to empower and support patients to help them take control of their asthma. Over one million people in Japan live with asthma and AstraZeneca’s app aims to help patients better manage their condition and adhere to their management plans, leading to a better quality of life. We are proud to be an integral part of this initiative and look forward to working with AstraZeneca on the integration process and launch of this important patient support program.”
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
- ResApp (ASX:RAP) share price jumps on COVID-19 app plans
- Why Flight Centre, Qantas, ResApp, & Volpara are racing higher
- Why the ResApp (ASX:RAP) share price is sinking 5% today
- Why the ResApp (ASX:RAP) share price opened 10% higher today
- Here’s why the Resapp (ASX:RAP) share price closed 5% lower
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.